Torley Helen, President and CEO of Halozyme Therapeutics ($HALO), sold about $31.8 million in company shares through 61 open market transactions over the last year. Her most recent sale occurred on March 4, 2026. These sales rank her 465th among 11,678 insiders in our database by total value sold, well above the average of $8.6 million per insider and six transactions. She made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| April 2, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Option to Purchase Common Stock | 20000 | $12.07 | 111,923.0000 | 123,904,000 | 15.16% | 0.02% |
| April 1, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 20000 | $12.07 | 787,780.0000 | 123,904,000 | 2.60% | 0.02% |
| April 1, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 19000 | $65.36 | 768,780.0000 | 123,904,000 | 2.41% | 0.02% |
| April 1, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 1000 | $65.71 | 767,780.0000 | 123,904,000 | 0.13% | 0.00% |
| April 2, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 20000 | $12.07 | 787,780.0000 | 123,904,000 | 2.60% | 0.02% |
| April 2, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 15800 | $64.06 | 771,980.0000 | 123,904,000 | 2.01% | 0.01% |
| April 2, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 4200 | $64.89 | 767,780.0000 | 123,904,000 | 0.54% | 0.00% |
| April 1, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Option to Purchase Common Stock | 20000 | $12.07 | 131,923.0000 | 123,904,000 | 13.16% | 0.02% |
| March 2, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 20000 | $12.07 | 787,780.0000 | 123,904,000 | 2.60% | 0.02% |
| March 2, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 15322 | $69.80 | 768,358.0000 | 123,904,000 | 1.96% | 0.01% |
| March 2, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 578 | $70.46 | 767,780.0000 | 123,904,000 | 0.08% | 0.00% |
| March 3, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 20000 | $12.07 | 787,780.0000 | 123,904,000 | 2.60% | 0.02% |
| March 3, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 13481 | $68.85 | 774,299.0000 | 123,904,000 | 1.71% | 0.01% |
| March 3, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 6519 | $69.33 | 767,780.0000 | 123,904,000 | 0.84% | 0.01% |
| March 4, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 10000 | $12.07 | 777,780.0000 | 123,904,000 | 1.30% | 0.01% |
| March 4, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 7329 | $69.94 | 770,451.0000 | 123,904,000 | 0.94% | 0.01% |
| March 4, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 2671 | $70.95 | 767,780.0000 | 123,904,000 | 0.35% | 0.00% |
| March 2, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Option to Purchase Common Stock | 20000 | $12.07 | 181,923.0000 | 123,904,000 | 9.90% | 0.02% |
| March 3, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Option to Purchase Common Stock | 20000 | $12.07 | 161,923.0000 | 123,904,000 | 10.99% | 0.02% |
| March 4, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Option to Purchase Common Stock | 10000 | $12.07 | 151,923.0000 | 123,904,000 | 6.18% | 0.01% |
| March 2, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 4100 | $69.20 | 783,680.0000 | 123,904,000 | 0.52% | 0.00% |
| Feb. 20, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | F | Common Stock | 9040 | $70.98 | 757,448.0000 | 123,904,000 | 1.18% | 0.01% |
| Feb. 23, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 22436 | $0.00 | 779,884.0000 | 123,904,000 | 2.96% | 0.02% |
| Feb. 23, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | F | Common Stock | 12104 | $70.64 | 767,780.0000 | 123,904,000 | 1.55% | 0.01% |
| Feb. 20, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Restricted Stock Units | 16757 | $0.00 | 50,270.0000 | 123,904,000 | 25.00% | 0.01% |
| Feb. 23, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Restricted Stock Units | 22436 | $0.00 | 44,872.0000 | 123,904,000 | 33.33% | 0.02% |
| Feb. 20, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 16757 | $0.00 | 766,488.0000 | 123,904,000 | 2.24% | 0.01% |
| Feb. 16, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | F | Common Stock | 9104 | $79.44 | 726,165.0000 | 123,904,000 | 1.24% | 0.01% |
| Feb. 16, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Performance Stock Units | 51171 | $0.00 | 0.0000 | 123,904,000 | 100.00% | 0.04% |
| Feb. 16, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Restricted Stock Units | 16875 | $0.00 | 16,874.0000 | 123,904,000 | 50.00% | 0.01% |
| Feb. 16, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Restricted Stock Units | 21009 | $0.00 | 0.0000 | 123,904,000 | 100.00% | 0.02% |
| Feb. 16, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | F | Common Stock | 27605 | $79.44 | 749,731.0000 | 123,904,000 | 3.55% | 0.02% |
| Feb. 16, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 51171 | $0.00 | 777,336.0000 | 123,904,000 | 7.05% | 0.04% |
| Feb. 16, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 16875 | $0.00 | 735,269.0000 | 123,904,000 | 2.35% | 0.01% |
| Feb. 16, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | F | Common Stock | 11334 | $79.44 | 718,394.0000 | 123,904,000 | 1.55% | 0.01% |
| Feb. 16, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 21009 | $0.00 | 729,728.0000 | 123,904,000 | 2.96% | 0.02% |
| Feb. 9, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | A | Option to Purchase Common Stock | 53847 | $0.00 | 53,847.0000 | 123,904,000 | 9999.99% | 0.04% |
| Feb. 9, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | A | Performance Stock Units | 19807 | $0.00 | 51,171.0000 | 123,904,000 | 63.15% | 0.02% |
| Feb. 9, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | A | Performance Stock Units | 24985 | $0.00 | 144,400.0000 | 123,904,000 | 20.92% | 0.02% |
| Feb. 9, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | A | Performance Stock Units | 92714 | $0.00 | 92,714.0000 | 123,904,000 | 9999.99% | 0.07% |
| Feb. 9, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | A | Restricted Stock Units | 50013 | $0.00 | 50,013.0000 | 123,904,000 | 9999.99% | 0.04% |
| Feb. 5, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Option to Purchase Common Stock | 10000 | $12.07 | 201,923.0000 | 123,904,000 | 4.72% | 0.01% |
| Feb. 4, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 20000 | $12.07 | 728,719.0000 | 123,904,000 | 2.82% | 0.02% |
| Feb. 4, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 10100 | $77.54 | 708,719.0000 | 123,904,000 | 1.41% | 0.01% |
| Feb. 3, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 2551 | $74.88 | 726,168.0000 | 123,904,000 | 0.35% | 0.00% |
| Feb. 3, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 20000 | $12.07 | 728,719.0000 | 123,904,000 | 2.82% | 0.02% |
| Feb. 4, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Option to Purchase Common Stock | 20000 | $12.07 | 211,923.0000 | 123,904,000 | 8.62% | 0.02% |
| Feb. 4, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 9900 | $76.94 | 718,819.0000 | 123,904,000 | 1.36% | 0.01% |
| Feb. 3, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Option to Purchase Common Stock | 20000 | $12.07 | 231,923.0000 | 123,904,000 | 7.94% | 0.02% |
| Feb. 5, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 4624 | $78.94 | 708,719.0000 | 123,904,000 | 0.65% | 0.00% |
| Feb. 5, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 5376 | $78.38 | 713,343.0000 | 123,904,000 | 0.75% | 0.00% |
| Feb. 5, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 10000 | $12.07 | 718,719.0000 | 123,904,000 | 1.41% | 0.01% |
| Feb. 3, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 9659 | $75.94 | 716,509.0000 | 123,904,000 | 1.33% | 0.01% |
| Feb. 3, 2026 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 7790 | $76.73 | 708,719.0000 | 123,904,000 | 1.09% | 0.01% |
| Dec. 9, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | A | Performance Stock Units | 165522 | $0.00 | 165,522.0000 | 124,449,000 | 9999.99% | 0.13% |
| Dec. 1, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 10406 | $68.51 | 714,882.0000 | 124,449,000 | 1.43% | 0.01% |
| Nov. 26, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | G | Common Stock | 25000 | $0.00 | 708,719.0000 | 124,449,000 | 3.41% | 0.02% |
| Dec. 1, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 500 | $70.36 | 708,980.0000 | 124,449,000 | 0.07% | 0.00% |
| Dec. 1, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 261 | $71.60 | 708,719.0000 | 124,449,000 | 0.04% | 0.00% |
| Dec. 1, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Option to Purchase Common Stock | 16569 | $8.11 | 0.0000 | 124,449,000 | 100.00% | 0.01% |
| Dec. 1, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 5402 | $69.44 | 709,480.0000 | 124,449,000 | 0.76% | 0.00% |
| Dec. 1, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 16569 | $8.11 | 725,288.0000 | 124,449,000 | 2.34% | 0.01% |
| Nov. 11, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 4000 | $68.80 | 745,219.0000 | 124,449,000 | 0.53% | 0.00% |
| Nov. 11, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 11500 | $69.73 | 733,719.0000 | 124,449,000 | 1.54% | 0.01% |
| Nov. 12, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 20000 | $8.11 | 753,719.0000 | 124,449,000 | 2.73% | 0.02% |
| Nov. 12, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 12718 | $70.22 | 741,001.0000 | 124,449,000 | 1.69% | 0.01% |
| Nov. 12, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 6784 | $71.09 | 734,217.0000 | 124,449,000 | 0.92% | 0.01% |
| Nov. 12, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 498 | $71.67 | 733,719.0000 | 124,449,000 | 0.07% | 0.00% |
| Nov. 10, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Option to Purchase Common Stock | 20000 | $8.11 | 56,569.0000 | 124,449,000 | 26.12% | 0.02% |
| Nov. 11, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Option to Purchase Common Stock | 20000 | $8.11 | 36,569.0000 | 124,449,000 | 35.36% | 0.02% |
| Nov. 12, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Option to Purchase Common Stock | 20000 | $8.11 | 16,569.0000 | 124,449,000 | 54.69% | 0.02% |
| Nov. 10, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 20000 | $8.11 | 753,719.0000 | 124,449,000 | 2.73% | 0.02% |
| Nov. 10, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 19900 | $68.71 | 733,819.0000 | 124,449,000 | 2.64% | 0.02% |
| Nov. 10, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 100 | $69.30 | 733,719.0000 | 124,449,000 | 0.01% | 0.00% |
| Nov. 11, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 20000 | $8.11 | 753,719.0000 | 124,449,000 | 2.73% | 0.02% |
| Nov. 11, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 4500 | $67.89 | 749,219.0000 | 124,449,000 | 0.60% | 0.00% |
| Oct. 2, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 2400 | $72.07 | 734,519.0000 | 124,449,000 | 0.33% | 0.00% |
| Oct. 2, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 100 | $74.67 | 733,719.0000 | 124,449,000 | 0.01% | 0.00% |
| Oct. 3, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 20000 | $8.11 | 753,719.0000 | 124,449,000 | 2.73% | 0.02% |
| Oct. 3, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 14235 | $68.47 | 739,484.0000 | 124,449,000 | 1.89% | 0.01% |
| Oct. 3, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 2334 | $69.83 | 737,150.0000 | 124,449,000 | 0.32% | 0.00% |
| Oct. 3, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 2707 | $70.58 | 734,443.0000 | 124,449,000 | 0.37% | 0.00% |
| Oct. 3, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 724 | $71.67 | 733,719.0000 | 124,449,000 | 0.10% | 0.00% |
| Oct. 1, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Option to Purchase Common Stock | 20000 | $8.11 | 116,569.0000 | 124,449,000 | 14.64% | 0.02% |
| Oct. 2, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Option to Purchase Common Stock | 20000 | $8.11 | 96,569.0000 | 124,449,000 | 17.16% | 0.02% |
| Oct. 3, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Option to Purchase Common Stock | 20000 | $8.11 | 76,569.0000 | 124,449,000 | 20.71% | 0.02% |
| Oct. 1, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 20000 | $8.11 | 753,719.0000 | 124,449,000 | 2.73% | 0.02% |
| Oct. 1, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 11705 | $75.11 | 742,014.0000 | 124,449,000 | 1.55% | 0.01% |
| Oct. 1, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 8295 | $75.69 | 733,719.0000 | 124,449,000 | 1.12% | 0.01% |
| Oct. 2, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 20000 | $8.11 | 753,719.0000 | 124,449,000 | 2.73% | 0.02% |
| Oct. 2, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 6600 | $70.51 | 747,119.0000 | 124,449,000 | 0.88% | 0.01% |
| Oct. 2, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 10200 | $71.28 | 736,919.0000 | 124,449,000 | 1.37% | 0.01% |
| Oct. 2, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 700 | $73.24 | 733,819.0000 | 124,449,000 | 0.10% | 0.00% |
| Sept. 2, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 16288 | $73.70 | 737,131.0000 | 129,424,000 | 2.16% | 0.01% |
| Sept. 4, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Option to Purchase Common Stock | 20000 | $8.11 | 136,569.0000 | 129,424,000 | 12.77% | 0.02% |
| Sept. 3, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Option to Purchase Common Stock | 20000 | $8.11 | 156,569.0000 | 129,424,000 | 11.33% | 0.02% |
| Sept. 2, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 20000 | $8.11 | 753,719.0000 | 129,424,000 | 2.73% | 0.02% |
| Sept. 2, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 300 | $72.49 | 753,419.0000 | 129,424,000 | 0.04% | 0.00% |
| Sept. 2, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Option to Purchase Common Stock | 20000 | $8.11 | 176,569.0000 | 129,424,000 | 10.17% | 0.02% |
| Sept. 4, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 2300 | $75.22 | 733,719.0000 | 129,424,000 | 0.31% | 0.00% |
| Sept. 4, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 7800 | $74.33 | 736,019.0000 | 129,424,000 | 1.05% | 0.01% |
| Sept. 4, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 9900 | $73.54 | 743,819.0000 | 129,424,000 | 1.31% | 0.01% |
| Sept. 4, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 20000 | $8.11 | 753,719.0000 | 129,424,000 | 2.73% | 0.02% |
| Sept. 3, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 10500 | $74.63 | 733,719.0000 | 129,424,000 | 1.41% | 0.01% |
| Sept. 3, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 9500 | $74.22 | 744,219.0000 | 129,424,000 | 1.26% | 0.01% |
| Sept. 3, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 20000 | $8.11 | 753,719.0000 | 129,424,000 | 2.73% | 0.02% |
| Sept. 2, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 3412 | $74.15 | 733,719.0000 | 129,424,000 | 0.46% | 0.00% |
| Aug. 11, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 20000 | $8.11 | 753,719.0000 | 129,424,000 | 2.73% | 0.02% |
| Aug. 11, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 1283 | $63.60 | 733,719.0000 | 129,424,000 | 0.17% | 0.00% |
| Aug. 11, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 18717 | $63.01 | 735,002.0000 | 129,424,000 | 2.48% | 0.01% |
| Aug. 13, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Option to Purchase Common Stock | 20000 | $8.11 | 196,569.0000 | 129,424,000 | 9.23% | 0.02% |
| Aug. 12, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Option to Purchase Common Stock | 20000 | $8.11 | 216,569.0000 | 129,424,000 | 8.45% | 0.02% |
| Aug. 11, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Option to Purchase Common Stock | 20000 | $8.11 | 236,569.0000 | 129,424,000 | 7.80% | 0.02% |
| Aug. 13, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 5052 | $64.83 | 733,719.0000 | 129,424,000 | 0.68% | 0.00% |
| Aug. 13, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 14948 | $64.15 | 738,771.0000 | 129,424,000 | 1.98% | 0.01% |
| Aug. 13, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 20000 | $8.11 | 753,719.0000 | 129,424,000 | 2.73% | 0.02% |
| Aug. 12, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 6958 | $64.00 | 733,719.0000 | 129,424,000 | 0.94% | 0.01% |
| Aug. 12, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 13042 | $63.24 | 740,677.0000 | 129,424,000 | 1.73% | 0.01% |
| Aug. 12, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 20000 | $8.11 | 753,719.0000 | 129,424,000 | 2.73% | 0.02% |
| July 10, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 4254 | $56.74 | 749,465.0000 | 129,424,000 | 0.56% | 0.00% |
| July 10, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 15746 | $57.62 | 733,719.0000 | 129,424,000 | 2.10% | 0.01% |
| July 8, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Option to Purchase Common Stock | 20000 | $8.11 | 296,569.0000 | 129,424,000 | 6.32% | 0.02% |
| July 9, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Option to Purchase Common Stock | 20000 | $8.11 | 276,569.0000 | 129,424,000 | 6.74% | 0.02% |
| July 10, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Option to Purchase Common Stock | 20000 | $8.11 | 256,569.0000 | 129,424,000 | 7.23% | 0.02% |
| July 8, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 20000 | $8.11 | 753,719.0000 | 129,424,000 | 2.73% | 0.02% |
| July 8, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 3598 | $54.48 | 750,121.0000 | 129,424,000 | 0.48% | 0.00% |
| July 8, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 16402 | $55.74 | 733,719.0000 | 129,424,000 | 2.19% | 0.01% |
| July 9, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 20000 | $8.11 | 753,719.0000 | 129,424,000 | 2.73% | 0.02% |
| July 9, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 19792 | $56.43 | 733,927.0000 | 129,424,000 | 2.63% | 0.02% |
| July 9, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 208 | $57.08 | 733,719.0000 | 129,424,000 | 0.03% | 0.00% |
| July 10, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 20000 | $8.11 | 753,719.0000 | 129,424,000 | 2.73% | 0.02% |
| June 23, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 20000 | $52.57 | 733,719.0000 | 129,424,000 | 2.65% | 0.02% |
| June 20, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 20000 | $8.11 | 753,719.0000 | 129,424,000 | 2.73% | 0.02% |
| June 20, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 20000 | $52.96 | 733,719.0000 | 129,424,000 | 2.65% | 0.02% |
| June 23, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 20000 | $8.11 | 753,719.0000 | 129,424,000 | 2.73% | 0.02% |
| June 24, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 20000 | $8.11 | 753,719.0000 | 129,424,000 | 2.73% | 0.02% |
| June 24, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 4489 | $53.11 | 749,230.0000 | 129,424,000 | 0.60% | 0.00% |
| June 24, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 15511 | $53.91 | 733,719.0000 | 129,424,000 | 2.07% | 0.01% |
| June 20, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Option to Purchase Common Stock | 20000 | $8.11 | 356,569.0000 | 129,424,000 | 5.31% | 0.02% |
| June 23, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Option to Purchase Common Stock | 20000 | $8.11 | 336,569.0000 | 129,424,000 | 5.61% | 0.02% |
| June 24, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Option to Purchase Common Stock | 20000 | $8.11 | 316,569.0000 | 129,424,000 | 5.94% | 0.02% |
| Feb. 23, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | F | Common Stock | 12081 | $57.75 | 733,719.0000 | 129,424,000 | 1.62% | 0.01% |
| Feb. 23, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Restricted Stock Units | 22436 | $0.00 | 67,308.0000 | 129,424,000 | 25.00% | 0.02% |
| Feb. 23, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 22436 | $0.00 | 745,800.0000 | 129,424,000 | 3.10% | 0.02% |
| Feb. 20, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | A | Option to Purchase Common Stock | 71038 | $0.00 | 71,038.0000 | 129,424,000 | 9999.99% | 0.05% |
| Feb. 20, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | A | Restricted Stock Units | 67027 | $0.00 | 67,027.0000 | 129,424,000 | 9999.99% | 0.05% |
| Feb. 16, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 21009 | $0.00 | 726,889.0000 | 129,424,000 | 2.98% | 0.02% |
| Feb. 16, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | F | Common Stock | 11313 | $58.29 | 715,576.0000 | 129,424,000 | 1.56% | 0.01% |
| Feb. 16, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 16875 | $0.00 | 732,451.0000 | 129,424,000 | 2.36% | 0.01% |
| Feb. 16, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | F | Common Stock | 9087 | $58.29 | 723,364.0000 | 129,424,000 | 1.24% | 0.01% |
| Feb. 15, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Restricted Stock Units | 13092 | $0.00 | 0.0000 | 129,424,000 | 100.00% | 0.01% |
| Feb. 16, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Performance Stock Units | 71810 | $0.00 | 0.0000 | 129,424,000 | 100.00% | 0.06% |
| Feb. 16, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Restricted Stock Units | 16875 | $0.00 | 33,749.0000 | 129,424,000 | 33.33% | 0.01% |
| Feb. 16, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Restricted Stock Units | 21009 | $0.00 | 21,009.0000 | 129,424,000 | 50.00% | 0.02% |
| Feb. 15, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 13092 | $0.00 | 679,836.0000 | 129,424,000 | 1.96% | 0.01% |
| Feb. 15, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | F | Common Stock | 7098 | $58.29 | 672,738.0000 | 129,424,000 | 1.04% | 0.01% |
| Feb. 16, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 71810 | $0.00 | 744,548.0000 | 129,424,000 | 10.67% | 0.06% |
| Feb. 16, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | F | Common Stock | 38668 | $58.29 | 705,880.0000 | 129,424,000 | 5.19% | 0.03% |
| Feb. 12, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | A | Performance Stock Units | 96155 | $0.00 | 96,155.0000 | 129,424,000 | 9999.99% | 0.07% |
| Feb. 12, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | A | Performance Stock Units | 24957 | $0.00 | 71,810.0000 | 129,424,000 | 53.27% | 0.02% |
| Feb. 12, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | A | Performance Stock Units | 20008 | $0.00 | 31,364.0000 | 129,424,000 | 176.19% | 0.02% |
| Feb. 12, 2025 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | A | Performance Stock Unit | 23260 | $0.00 | 23,260.0000 | 129,424,000 | 9999.99% | 0.02% |
| Nov. 29, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | G | Common Stock | 10000 | $0.00 | 666,744.0000 | 130,134,000 | 1.48% | 0.01% |
| Oct. 8, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Option to Purchase Common Stock | 10000 | $13.87 | 10,000.0000 | 130,134,000 | 50.00% | 0.01% |
| Oct. 8, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 10000 | $13.87 | 686,744.0000 | 130,134,000 | 1.48% | 0.01% |
| Oct. 8, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 9100 | $53.94 | 677,644.0000 | 130,134,000 | 1.33% | 0.01% |
| Oct. 8, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 900 | $54.57 | 676,744.0000 | 130,134,000 | 0.13% | 0.00% |
| Oct. 9, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 10000 | $13.87 | 686,744.0000 | 130,134,000 | 1.48% | 0.01% |
| Oct. 9, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 5981 | $51.85 | 680,763.0000 | 130,134,000 | 0.87% | 0.00% |
| Oct. 9, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 1615 | $53.31 | 679,148.0000 | 130,134,000 | 0.24% | 0.00% |
| Oct. 9, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 2404 | $53.91 | 676,744.0000 | 130,134,000 | 0.35% | 0.00% |
| Oct. 9, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Option to Purchase Common Stock | 10000 | $13.87 | 0.0000 | 130,134,000 | 100.00% | 0.01% |
| Sept. 24, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Option to Purchase Common Stock | 10000 | $13.87 | 40,000.0000 | 134,197,000 | 20.00% | 0.01% |
| Sept. 26, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Option to Purchase Common Stock | 10000 | $13.87 | 20,000.0000 | 134,197,000 | 33.33% | 0.01% |
| Sept. 25, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Option to Purchase Common Stock | 10000 | $13.87 | 30,000.0000 | 134,197,000 | 25.00% | 0.01% |
| Sept. 26, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 10000 | $56.10 | 676,744.0000 | 134,197,000 | 1.46% | 0.01% |
| Sept. 26, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 10000 | $13.87 | 686,744.0000 | 134,197,000 | 1.48% | 0.01% |
| Sept. 25, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 10000 | $56.34 | 676,744.0000 | 134,197,000 | 1.46% | 0.01% |
| Sept. 25, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 10000 | $13.87 | 686,744.0000 | 134,197,000 | 1.48% | 0.01% |
| Sept. 24, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 10000 | $58.21 | 676,744.0000 | 134,197,000 | 1.46% | 0.01% |
| Sept. 24, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 10000 | $13.87 | 686,744.0000 | 134,197,000 | 1.48% | 0.01% |
| Sept. 12, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Option to Purchase Common Stock | 10000 | $13.87 | 50,000.0000 | 134,197,000 | 16.67% | 0.01% |
| Sept. 11, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 10000 | $13.87 | 686,744.0000 | 134,197,000 | 1.48% | 0.01% |
| Sept. 10, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 10000 | $59.09 | 676,744.0000 | 134,197,000 | 1.46% | 0.01% |
| Sept. 11, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 10000 | $59.09 | 676,744.0000 | 134,197,000 | 1.46% | 0.01% |
| Sept. 10, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 10000 | $13.87 | 686,744.0000 | 134,197,000 | 1.48% | 0.01% |
| Sept. 12, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 10000 | $13.87 | 686,744.0000 | 134,197,000 | 1.48% | 0.01% |
| Sept. 12, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 10000 | $59.20 | 676,744.0000 | 134,197,000 | 1.46% | 0.01% |
| Sept. 10, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Option to Purchase Common Stock | 10000 | $13.87 | 70,000.0000 | 134,197,000 | 12.50% | 0.01% |
| Sept. 11, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Option to Purchase Common Stock | 10000 | $13.87 | 60,000.0000 | 134,197,000 | 14.29% | 0.01% |
| Aug. 14, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 6537 | $57.73 | 676,944.0000 | 134,197,000 | 0.96% | 0.00% |
| Aug. 13, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 10000 | $13.87 | 686,744.0000 | 134,197,000 | 1.48% | 0.01% |
| Aug. 13, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 10000 | $56.25 | 676,744.0000 | 134,197,000 | 1.46% | 0.01% |
| Aug. 14, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 10000 | $13.87 | 686,744.0000 | 134,197,000 | 1.48% | 0.01% |
| Aug. 14, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 3263 | $56.22 | 683,481.0000 | 134,197,000 | 0.48% | 0.00% |
| Aug. 14, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 200 | $58.17 | 676,744.0000 | 134,197,000 | 0.03% | 0.00% |
| Aug. 15, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 10000 | $13.87 | 686,744.0000 | 134,197,000 | 1.48% | 0.01% |
| Aug. 15, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | S | Common Stock | 10000 | $57.95 | 676,744.0000 | 134,197,000 | 1.46% | 0.01% |
| Aug. 13, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Option to Purchase Common Stock | 10000 | $13.87 | 100,000.0000 | 134,197,000 | 9.09% | 0.01% |
| Aug. 14, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Option to Purchase Common Stock | 10000 | $13.87 | 90,000.0000 | 134,197,000 | 10.00% | 0.01% |
| Aug. 15, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Option to Purchase Common Stock | 10000 | $13.87 | 80,000.0000 | 134,197,000 | 11.11% | 0.01% |
| Feb. 23, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | A | Option to Purchase Common Stock | 93002 | $0.00 | 93,002.0000 | 134,197,000 | 9999.99% | 0.07% |
| Feb. 23, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | A | Restricted Stock Units | 89744 | $0.00 | 89,744.0000 | 134,197,000 | 9999.99% | 0.07% |
| Feb. 16, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 21009 | $0.00 | 680,231.0000 | 134,197,000 | 3.19% | 0.02% |
| Feb. 16, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | F | Common Stock | 11292 | $36.10 | 668,939.0000 | 134,197,000 | 1.66% | 0.01% |
| Feb. 16, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 16875 | $0.00 | 685,814.0000 | 134,197,000 | 2.52% | 0.01% |
| Feb. 16, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Restricted Stock Units | 21009 | $0.00 | 42,018.0000 | 134,197,000 | 33.33% | 0.02% |
| Feb. 16, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | F | Common Stock | 9070 | $36.10 | 676,744.0000 | 134,197,000 | 1.32% | 0.01% |
| Feb. 16, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Restricted Stock Units | 16875 | $0.00 | 50,624.0000 | 134,197,000 | 25.00% | 0.01% |
| Feb. 15, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | F | Common Stock | 7036 | $35.91 | 644,060.0000 | 134,197,000 | 1.08% | 0.01% |
| Feb. 15, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | F | Common Stock | 17619 | $35.91 | 659,222.0000 | 134,197,000 | 2.60% | 0.01% |
| Feb. 15, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Restricted Stock Units | 13092 | $0.00 | 13,092.0000 | 134,197,000 | 50.00% | 0.01% |
| Feb. 15, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 13092 | $0.00 | 651,096.0000 | 134,197,000 | 2.05% | 0.01% |
| Feb. 15, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | A | Common Stock | 32781 | $0.00 | 676,841.0000 | 134,197,000 | 5.09% | 0.02% |
| Feb. 10, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Restricted Stock Units | 31281 | $0.00 | 0.0000 | 134,197,000 | 100.00% | 0.02% |
| Feb. 10, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | F | Common Stock | 16943 | $35.49 | 638,004.0000 | 134,197,000 | 2.59% | 0.01% |
| Feb. 10, 2024 | HALOZYME THERAPEUTICS, INC. | $HALO | Torley Helen | PRESIDENT AND CEO | M | Common Stock | 31281 | $0.00 | 654,947.0000 | 134,197,000 | 5.02% | 0.02% |